Thus, the DGAT1 inhibitor is expected to become a novel treatment option for obesity and type-2 diabetes mellitus (T2DM) without the severe adverse events associated with the DGAT2 inhibition. The gene discussed is DGAT1; the disease is obesity due to melanocortin 4 receptor deficiency.